Gibson Dunn & Crutcher advised Merck on the transaction and Wilson Sonsini Goodrich & Rosati advised LaNova Medicines. Merck (NYSE: MRK), known as MSD outside of...
Merck’s License Agreement with LaNova
Merck’s Acquisition of Eyebiotech
Skadden advised Eyebiotech Limited, while Gibson, Dunn & Crutcher advised Merck the deal. Merck, known as MSD outside of the United States and Canada, and Eyebiotech...
Bora Pharmaceuticals’ $210 Million Acquisition of Upsher-Smith Laboratories
Gibson, Dunn & Crutcher LLP is representing Bora Pharmaceuticals in its acquisition of Upsher-Smith Laboratories. Bora Pharmaceuticals Co., Ltd. announced the acquisition of Upsher-Smith Laboratories, Inc., a generics manufacturer...